PM
NAVB

Platinum Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Platinum Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,050
Closed -$2.5M – 148
2014
Q1 		$2.5M Buy
+3,050
New +$116K 1.18% 31

Other funds holding NAVB

CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Platinum Management's NAVB Position: Q1 2016 in Review

Platinum Management increased its Navidea Biopharmaceuticals Inc. (NAVB) stake by 351% in Q1 2016, buying an estimated $11.7M and bringing the position to 778,797 shares worth $14.7M. The position accounts for 89.51% of the portfolio, ranked #1.

Platinum Management first reported a position in NAVB in Q2 2013 and has held it in 12 quarters since. The position peaked at $29M in Q3 2015. 74 funds tracked by Wall St. Rank hold NAVB as of Q1 2016.

  • Platinum Management held 778,797 shares of Navidea Biopharmaceuticals Inc. worth $14.7M as of Q1 2016.
  • Platinum Management bought 606,299 Navidea Biopharmaceuticals Inc. shares in Q1 2016, an estimated $11.7M.
  • Navidea Biopharmaceuticals Inc. made up 89.51% of Platinum Management's portfolio in Q1 2016, its #1 holding.
  • Platinum Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and has held it in 12 quarters since.
  • Platinum Management's Navidea Biopharmaceuticals Inc. position peaked at $29M in Q3 2015.
  • 74 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2016.

Based on Platinum Management's 13F filing for Q1 2016, filed 16 May 2016.